Search

Your search keyword '"Kleeberg, U.R."' showing total 130 results
Start Over Author "Kleeberg, U.R."
130 results on '"Kleeberg, U.R."'

1. Counseling cancer patients on complementary and alternative medicine: Background, theory, and implementation of nationwide counseling facilities

Author

Hübner, J., Muenstedt, K., Muecke, R., Micke, O., Stoll, C., Kleeberg, U.R., Buentzel, J., Dennert, G., Prott, F.J., and On behalf of PRIO (Working group Prevention and Integrative Oncology of the German Cancer Society) and AKTE (Working group Trace Elements of the German Society of Radiooncology (DEGRO)

Published
2013
Full Text
View/download PDF

14. Superior outcome of women with stage I/II cutaneous melanoma: Pooled analysis of four European organisation for research and treatment of cancer phase III trials

Author

Joosse, A. (Arjen), Collette, S. (Sandra), Suciu, S. (Stefan), Nijsten, T.E.C. (Tamar), Lejeune, F.J. (Ferdy), Kleeberg, U.R. (Ulrich), Coebergh, J.W.W. (Jan Willem), Eggermont, A.M.M. (Alexander), Vries, E. (Esther) de, Joosse, A. (Arjen), Collette, S. (Sandra), Suciu, S. (Stefan), Nijsten, T.E.C. (Tamar), Lejeune, F.J. (Ferdy), Kleeberg, U.R. (Ulrich), Coebergh, J.W.W. (Jan Willem), Eggermont, A.M.M. (Alexander), and Vries, E. (Esther) de

Abstract

Purpose: Several studies observed a female advantage in the prognosis of cutaneous melanoma, for which behavioral factors or an underlying biologic mechanism might be responsible. Using complete and reliable follow-up data from four phase III trials of the European Organisation for Research and Treatment of Cancer (EORTC) Melanoma Group, we explored the female advantage across multiple end points and in relation to other important prognostic indicators. Patients and Methods: Patients diagnosed with localized melanoma were included in EORTC adjuvant treatment trials 18832, 18871, 18952, and 18961 and randomly assigned during the period of 1984 to 2005. Cox proportional hazard models were used to calculate hazard ratios (HRs) and 95% CIs for women compared with men, adjusted for age, Breslow thickness, body site, ulceration, performed lymph node dissection, and treatment. Results: A total of 2,672 patients with stage I/II melanoma were included. Women had a highly consistent and independent advantage in overall survival (adjusted HR, 0.70; 95% CI, 0.59 to 0.83), disease-specific survival (adjusted HR, 0.74; 95% CI, 0.62 to 0.88), time to lymph node metastasis (adjusted HR, 0.70; 95% CI, 0.51 to 0.96), and time to distant metastasis (adjusted HR, 0.69; 95% CI, 0.59 to 0.81). Subgroup analysis showed that the female advantage was consistent across all prognostic subgroups (with the possible exception of head and neck melanomas) and in pre- and postmenopausal age groups. Conclusion: Women have a consistent and independent relative advantage in all aspects of the progression of localized melanoma of approximately 30%, most likely caused by an underlying biologic sex difference.

Published
2012
Full Text
View/download PDF

15. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.

Author

Keilholz, U., Punt, C.J.A., Gore, M., Kruit, W., Patel, P., Lienard, D., Thomas, J., Proebstle, T.M., Schmittel, A., Schadendorf, D., Velu, T., Negrier, S., Kleeberg, U.R., Lehman, F., Suciu, S., Eggermont, A.M.M., Keilholz, U., Punt, C.J.A., Gore, M., Kruit, W., Patel, P., Lienard, D., Thomas, J., Proebstle, T.M., Schmittel, A., Schadendorf, D., Velu, T., Negrier, S., Kleeberg, U.R., Lehman, F., Suciu, S., and Eggermont, A.M.M.

Abstract

Contains fulltext : 49220schadendorf.pdf (publisher's version ) (Closed access), BACKGROUND: Based on phase II trial results, chemoimmunotherapy combinations have become the preferred treatment for patients with metastatic melanoma in many institutions. This study was performed to determine whether interleukin-2 (IL-2) as a component of chemoimmunotherapy influences survival of patients with metastatic melanoma. PATIENTS AND METHODS: Patients with advanced metastatic melanoma were randomly assigned to receive dacarbazine 250 mg/m2 and cisplatin 30 mg/m2 on days 1 to 3 combined with interferon-alfa-2b 10 x 10(6) U/m2 subcutaneously on days 1 through 5 without (arm A) or with (arm B) a high-dose intravenous decrescendo regimen of IL-2 on days 5 through 10 (18 x 10(6) U/m2/6 hours, 18 x 10(6) U/m2/12 hours, 18 x 10(6) U/m2/24 hours, and 4.5 x 10(6) U/m2 for 3 x 24 hours). Treatment cycles were repeated in the absence of disease progression every 28 days to a maximum of four cycles. RESULTS: Three hundred sixty-three patients with advanced metastatic melanoma were accrued. The median survival was 9 months in both arms, with a 2-year survival rate of 12.9% and 17.6% in arms A and B, respectively (P = .32; hazard ratio, 0.90; 95% CI, 0.72 to 1.11). There was also no statistically significant difference regarding progression-free survival (median, 3.0 v 3.9 months) and response rate (22.8% v 20.8%). CONCLUSION: Despite its activity in melanoma as a single agent or in combination with interferon-alfa-2b, the chosen schedule of IL-2 added to the chemoimmunotherapy combination had no clinically relevant activity.

Published
2005

18. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis.

Author

Kleeberg, U.R., Suciu, S., Bröcker, E.B., Ruiter, D.J., Chartier, C., Lienard, D., Marsden, J., Schadendorf, D., Eggermont, A.M.M., Kleeberg, U.R., Suciu, S., Bröcker, E.B., Ruiter, D.J., Chartier, C., Lienard, D., Marsden, J., Schadendorf, D., and Eggermont, A.M.M.

Abstract

Contains fulltext : 58477schadendorf.pdf (publisher's version ) (Closed access), Between 1988 and 1996, the European Organisation for Research and Treatment of Cancer Melanoma Group (EORTC-MG) performed a prospective, randomised phase III adjuvant trial to evaluate the efficacy and toxicity of low dose recombinant interferon-alpha 2 b (rIFN-alpha2b) (1 MU) or recombinant interferon gamma (rIFN-gamma), (0.2 mg) both given subcutaneously (s.c.), every other day (qod), for 12 months in comparison with an untreated control group. The German Cancer Society (DKG) added a fourth arm with Iscador M, a popular mistletoe extract. High-risk stage II patients (thickness >3 mm) and stage III patients (positive lymph nodes) without distant metastasis were randomised and followed until their first progression or death. An intention-to-treat analysis was performed. From 1988 to 1996, a total of 830 patients were randomised: 423 in the three-arm EORTC 18871 trial and 407 patients in the four-arm DKG 80-1 trial. The median follow-up was 8.2 years and a total of 537 relapses and 475 deaths were reported. At 8 years, the disease-free interval (DFI) rate was 32.4% and the overall survival (OS) rate was 40.0%. In terms of the DFI, the hazard ratio estimates (95% Confidence Intervals (CI)) were: 1.04 (0.84, 1.30) for the comparison of rIFN-alpha2b versus control, 0.96 (0.77, 1.20) for rIFN-gamma versus control, and 1.32 (0.93, 1.87) for Iscador M versus control. In terms of OS, the corresponding estimates (95% CI) for the 3 treatment comparisons were: for IFN-alpha2b 0.96 (0.76, 1.21), for rIFN-gamma 0.87 (0.69, 1.10) and for Iscador M 1.21 (0.84, 1.75), respectively. The results show no clinical benefit for adjuvant treatment with low dose rIFN-alpha2b or rIFN-gamma or with Iscador M in high-risk melanoma patients.

Published
2004

22. High tPA-expression in primary melanoma of the limb correlates with good prognosis

Author

Ferrier, C.M., Suciu, S., Geloof, W. van, Straatman, H.M.P.M., Eggermont, A.M.M., Schraffordt Koops, H., Kroon, B.B., Lejeune, F.J., Kleeberg, U.R., Muijen, G.N.P. van, Ruiter, D.J., Ferrier, C.M., Suciu, S., Geloof, W. van, Straatman, H.M.P.M., Eggermont, A.M.M., Schraffordt Koops, H., Kroon, B.B., Lejeune, F.J., Kleeberg, U.R., Muijen, G.N.P. van, and Ruiter, D.J.

Abstract

Item does not contain fulltext

Published
2000

24. Pan- European, open-label dose titration study of fentanyl buccal tablet in patients with breakthrough cancer pain.

Author

Kleeberg, U.R., Davies, A., Jarosz, J., Mercadante, S., Poulain, P., O'Brien, T., Schneid, H., and Kress, H.G.

Abstract

Background: Fentanyl buccal tablet (FBT), a rapid onset opioid used to treat breakthrough cancer pain, must be titrated to an effective dose that provides adequate analgesia and minimizes undesirable events. This open ‐ label, randomized study compared the percentage of patients achieving an effective dose of FBT when starting titration at 100 or 200 μg. Methods: Opioid ‐ tolerant patients with chronic cancer ‐ related pain who experienced up to four breakthrough pain episodes daily were randomized to a starting dose of 100 or 200 μg for the titration period. The dose was increased until an effective dose (100, 200, 400, 600 or 800 μg) providing adequate analgesia with acceptable adverse events was achieved. Patients achieving an effective dose entered a treatment period during which they treated up to eight breakthrough pain episodes with their effective dose. Results: A total of 442 patients from 135 sites in seven European countries were screened. Non ‐ inferiority was established with the percentage of patients achieving an effective dose starting titration at 200 μg (81.4%) compared with the 100 ‐ μg (75.2%) starting dose. The most common effective doses of FBT were 200 μg (39.6%) and 400 μg (26.9%). No new safety concerns were identified with use of FBT at doses up to 800 μg per episode. Conclusions: This study involving a real clinical practice setting showed a similar percentage of patients safely achieving an effective dose by titration starting with 100 versus 200 μg of FBT. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

26. Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients

Author

Kölmel, K.F., primary, Grange, J.M., additional, Krone, B., additional, Mastrangelo, G., additional, Rossi, C.R., additional, Henz, B.M., additional, Seebacher, C., additional, Botev, I.N., additional, Niin, M., additional, Lambert, D., additional, Shafir, R., additional, Kokoschka, E.-M., additional, Kleeberg, U.R., additional, Gefeller, O., additional, and Pfahlberg, A., additional

Published
2005
Full Text
View/download PDF

27. ICI 182,780 (‘FASLODEX’) is at least as effective as anatrozole (Arimidex™) in post-menopausal women with advanced breast cancer progressing on prior endocrine treatment

Author

Howell, A., primary, Robertson, J.F.R., additional, Albano, J.Quaresma, additional, Aschermannova, A., additional, Mauriac, L., additional, Kleeberg, U.R., additional, Bergote, I., additional, Erikstein, B., additional, Webster, A., additional, and Morris, C., additional

Published
2001
Full Text
View/download PDF

31. A Randomized Phase III Study Comparing Weekly Folinic Acid(FA) and High-Dose 5-Fluorouracil (5-FU) with Monthly 5-FU/FA (days 1-5) in Untreated Patients with Metastatic Colorectal Carcinoma

Author

Weh, H.J., primary, Zschaber, R., additional, Braumann, D., additional, Hoelzer, P., additional, Hoffmann, R., additional, Becker, K., additional, Kleeberg, U.R., additional, Pompecki, R., additional, Hoffknecht, M., additional, Benner, A., additional, and Hossfeld, D.K., additional

Published
1998
Full Text
View/download PDF

42. Topically Applied Miltefosine (Hexadecylphosphocholine) in Patients with Skin-Metastasized Breast Cancer. A Phase II Study

Author

linger, C., primary, Herrmann, R., additional, Berdel, W.E., additional, Kleeberg, U.R., additional, Gatzemeier, U., additional, Illiger, H.J., additional, Wander, H.E., additional, Westerhausen, M., additional, Becher, R., additional, Bremer, K., additional, Rieche, K., additional, Essers, U., additional, Queißer, W., additional, Heidemann, E., additional, Fiebig, H.H., additional, Possinger, K., additional, Jourdain-Madl, B., additional, Heim, M.E., additional, and Edler, L., additional

Published
1993
Full Text
View/download PDF

47. Multizentrische prospektive kontrollierte Studie zur Therapie der chronisch myeloischen Leukämie. Vergleich von Busulfan, Hydroxyurea und Interferon alpha (Stand April 1990)

Author

Hehlmann, R., primary, Heimpel, H., additional, Heinze, B., additional, Georgii, A., additional, Kolb, H.J., additional, Hossfeld, D.K., additional, Wussow, P.v., additional, Hochhaus, A., additional, Grießhammer, M., additional, Diehl, V., additional, Wickramanayake, P.D., additional, Gallmeier, W., additional, Falge, C., additional, Essers, U., additional, Bergmann, L., additional, Meyer, P., additional, Walther, F., additional, Kanz, L., additional, Queißer, U., additional, Hohnloser, J., additional, Westerhausen, M., additional, Kleeberg, U.R., additional, Heilein, A., additional, Käbisch, A., additional, Heiss, F., additional, Zimmermann, R., additional, Meuret, G., additional, Tichelli, A., additional, Berdel, W.E., additional, Schmitz, N., additional, Tigges, F.-J., additional, Eimermacher, H., additional, Schmid, L., additional, Löffler, H., additional, Pralle, H., additional, Queißer, W., additional, Burkhardt, R., additional, Ansari, H., additional, and Hasford, J., additional

Published
1991
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results